Enabling Safer, More Accessible Protein Therapeutics Through DNA Medicine
Infirmacea is developing an ultra-safe DNA medicine platform designed to enable the body to produce therapeutic proteins internally using minimal amounts of DNA and patient-friendly delivery.
Our mission is to expand the applicability of protein therapeutics — particularly in settings where long-term safety, durability, and accessibility are essential.
The Challenge with Protein Therapeutics
Protein-based medicines have transformed care across many diseases. However, most require frequent injections or infusions, creating cumulative treatment burden and raising long-term safety considerations.
These limitations are especially pronounced in pediatric and chronic conditions, where patients may require therapy for decades.
Our Approach
Infirmacea’s platform leverages naked DNA as a therapeutic modality, selected for its favorable safety profile and manufacturing simplicity. To overcome historically limited gene expression, we developed a proprietary gene expression enhancer, gBoost™, which enables robust protein production from very small DNA doses.
Combined with needle-free delivery, our approach is designed to support sustained biological signaling while minimizing treatment burden.
Platform-Driven Exploration
Infirmacea is a platform-driven company. Rather than advancing a single product, we explore how our technology may be applied across disease areas that share common challenges—long-term treatment, safety sensitivity, and unmet medical need.
Our Focus AreaDisclaimer
The information on this website is provided for informational purposes only. All disease areas described are exploratory. No clinical development programs have been initiated.